Dr. Johnson is a medical oncologist who specializes in lung cancer, breast cancer, and experimental therapeutics, (developing and testing new anti-cancer treatment therapies). His clinical research efforts focus on the management of thoracic malignancies and the biology and treatment of breast cancers.
Despite major advances, current therapy does not help everyone diagnosed with breast cancer that has spread or recurred. Studying investigational drugs to determine if they can slow the growth of breast cancer tumors and understanding why some tumors fail to respond to treatment are some of Dr. Johnson's goals.
His clinical research efforts include not only new treatment regimens but also studying drugs that are currently approved for other diseases such as Celebrex (approved for treating arthritis). Although Celebrex is not considered therapeutic in treating lung cancer, Dr. Johnson hopes to learn important information that will prove useful in developing future treatments.
Dr. Johnson oversees a division that is in the forefront of cancer treatment and research. Our goal is to detect cancer at the earliest stages and suppress its growth before it becomes malignant as well as develop new treatment therapies that target specific defects in cancer cells while sparing healthy cells.
Dr. Johnson is a widely recognized investigator, the author of over 250 publications, editor or co-editor of numerous oncology textbooks and is actively involved in numerous professional associations including the American Society of Clinical Oncology (ASCO). Dr. Johnson is the Immediate Past President of ASCO which is the world's largest professional organization representing physicians who treat people with cancer. In 2004, Dr. Johnson was once again listed as one of the "top doctors" in the nation in America's Top Doctors rankings.
